SCIENTIFIC BOARD

Rakesh Dixit is a prominent expert in antibody-drug conjugates (ADCs) with over three decades of experience in biotech and pharmaceuticals. He currently leads Bionavigen, a consultancy specializing in the development of biologics, cell and gene therapies, and small molecule drugs. Previously, he held senior roles at major companies like Merck, Johnson & Johnson, and AstraZeneca’s MedImmune, where he played a key part in bringing several biologics and small-molecule therapies to market. His contributions to ADC research earned him the “Long-Standing Contributor to ADCs” award from the World ADC Forum in 2020

John Lambert is a leading authority in the field of antibody-drug conjugates (ADCs). He spent a significant portion of his career at ImmunoGen, where he served as Chief Scientific Officer from 2008 to 2015. During his tenure, he was instrumental in the development of key ADCs, including Kadcyla® for HER2-positive breast cancer and Elahere® for ovarian cancer. Lambert has authored over 120 scientific papers and remains active as a consultant and advisor in the biotech industry, contributing to the continued advancement of ADC therapies

John Stagg is a professor at Université de Montréal and a principal investigator at CHUM. He is a recognized leader in cancer immunology, particularly for identifying CD73 as a key therapeutic target in immuno-oncology. His research has contributed to the development of therapies currently in clinical trials. Stagg co-founded Surface Oncology and is a board member of BioCanRx